The effect of a preservative-free prostaglandin analogue on the condition of the ocular surface in patients with glaucoma
https://doi.org/10.53432/2078-4104-2023-22-4-60-66
Abstract
PURPOSE. The study aimed to evaluate the antihypertensive effectiveness and the condition of the ocular surface in patients with glaucoma during monotherapy with the drug Traviolan® (travaprost 0.05%).
METHODS. This longitudinal, randomized, prospective study included 27 patients (59.6% women, 40.4% men; mean age 64.1±6.4) with uncompensated primary open-angle glaucoma in early and moderate stages receiving mono-therapy with β-blockers or carbonic anhydrase inhibitors. This was a longitudinal, randomized, prospective, observational study. All patients underwent a complete ophthalmological examination and assessment of dry eye symptoms using a questionnaire (Ocular Surface Disease Index, OSDI). An objective assessment of the condition of the ocular surface was carried out using the Sirius corneal topography device, which is used for assessment of tear film breakup time (TBUT). All patients were re-examined after 12 weeks.
RESULTS. Intraocular pressure was significantly reduced at all study visits and amounted to 5.9±2.8 mm Hg at week
12 (25.9%). There was a significant reduction in symptoms of dry eye, irritation, itching, and foreign body sensation (p<0.05 for each parameter). A significant improvement was also noted in terms of the condition of the ocular surface, and in most patients the symptom complex was classified as mild dry eye syndrome (p<0.05). Additionally, there was also a significant improvement in the OSDI score (p<0.05) with a mean of 17.95±5.35 points. The tear film breakup time by the end of observation increased by 4.1±2.3 sec and amounted to 7.4±3.1 sec.
CONCLUSION. The drug Traviolan® has high antihypertensive effectiveness and good tolerability, and improves the condition of the ocular surface.
About the Authors
L. L. Arutyunyan
Russian Medical Academy of Continuous Professional Education; Eye care center “East Sight Recovery”
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor at the Academic Department of Ophthalmology, Russian Medical Academy of Continuous Professional Education; Head of the Diagnostics Department
2/1 Barricadnaya St., Moscow, 125993
10 bld. 1 Poliny Osipenko St., Moscow, 123007
S. Yu. Anisimova
Eye care center “East Sight Recovery”
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Director
10 bld. 1 Poliny Osipenko St., Moscow, 123007
S. I. Anisimov
A.I. Yevdokimov Moscow State University of Medicine and Dentristy; Eye care center “East Sight Recovery”
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor at the Academic Department of Eye Diseases, A.I. Yevdokimov Moscow State University of Medicine and Dentristy; Scientific Director, Eye care center “East Sight Recovery”
20/1 Delegatskaya St., Moscow, 1274733
10 bld. 1 Poliny Osipenko St., Moscow, 123007
D. A. Teuvazhukova
Kabardino-Balkarian State University named after H.M. Berbekov
Russian Federation
Russian Federation
postgraduate student, Assistant for ophthalmology course at the Academic Department of General Surgery of the Medical Faculty
173 Chernishevskogo St., Nalchik, 360004
References
1. Weinreb R.N., Aung T., Medeiros F.A. The pathophysiology and treatment of glaucoma. JAMA 2014; 311(18):1901-1911. https://doi.org/10.1001/jama.2014.3192
2. Clinical Guidelines «Primary open angle glaucoma». 2020 (16.02.2021),
3. Approved by the Ministry of Health of the Russian Federation.
4. Reis T.F., Paula J.S., Furtado J.M. Primary glaucomas in adults: Epidemiology and public health — A review. Clin Exp Ophthalmol 2022; 50(2):128-142. https://doi.org/10.1111/ceo.14040
5. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
6. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90(3):262-267. https://doi.org/10.1136/bjo.2005.081224
7. Neroev V.V., Mikhailova L.A. Ophthalmic morbidity in Russia. In: «Ophthalmology. National giudeline». S.E. Avetisov, E.A. Egorov, L.K. Moshetova, Kh.P. Takhchidi, eds. Moscow, GEOTAR-Media, 2018. Pp. 15-19.
8. Van Veldhuisen P. E. F., Gaasterland, D. E. et al. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-440.
9. Dikopf M.S., Vajaranant T.S., Edward D.P. Topical treatment of glaucoma: Established and emerging pharmacology. Expert Opin Pharmacother 2017; 18(9):885–898. https://doi.org/10.1080/14656566.2017.1328498
10. Vicente A., Prud'homme S., Ferreira J. et al. Open-angle glaucoma: Drug development pipeline during the last 20 years (1995-2015). Ophthalmic Res 2017; 57(4):201-207. https://doi.org/10.1159/000453527
11. Winkler N.S., Fautsch M.P. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther 2014; 30(2–3):102-109. https://doi.org/10.1089/jop.2013.0179
12. Lemij H.G., Hoevenaars J.G., van der Windt C., et al. Patient satisfaction with glaucoma therapy: Reality or myth? Clin Ophthalmol 2015; 9:785-793. https://doi.org/10.2147/OPTH.S78918
13. Batra R., Tailor R., Mohamed S. Ocular surface disease exacerbated glaucoma: Optimizing the ocular surface improves intraocular pressure control. J Glaucoma 2014; 23(1):56-60. https://doi.org/10.1097/IJG.0b013e318264cd68
14. Mylla Boso A.L., Gasperi E., Fernandes L. et al. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol 2020; 14:103-111. https://doi.org/10.2147/OPTH.S229815
15. Willcox MD.P., Argüeso P., Georgiev G.A. et al. TFOS DEWS II tear film report. Ocul Surf 2017; 15(3):366-403. https://doi.org/10.1016/j.jtos.2017.03.006
16. Asiedu K., Abu S.L. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review. J Curr Ophthalmol 2019; 31(1):8-15. https://doi.org/10.1016/j.joco.2018.07.003
17. Baudouin C., Renard J.P., Nordmann J.P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol 2013; 23:47-54. https://doi.org/10.5301/ejo.5000181
18. Thygesen J. Glaucoma therapy: preservative-free for all? Clin Ophthalmol 2018; 12:707-717. https://doi.org/10.2147/OPTH.S150816.
19. Brzhesky V.V., Radhuan M. Glaucoma and dry eye syndrome. Oftalmologičeskie vedomosti 2014; 7(2):37-49.
20. Misiuk-Hojlo M., Pomorska M., Mulak M. et al. The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol 2019; 29(2):210-215. https://doi.org/10.1177/1120672118785280.
21. Hollo G., Katsanos A., Boboridis K.G., Irkec M., Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: Efficacy, Safety and Potential Advantages. Drugs 2018; 78(1):39-64. https://doi.org/10.1007/s40265-017-0843-9
22. Mylla Boso A.L., Gasperi E., Fernandes L. et al. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol 2020; 14:103–111. https://doi.org/10.2147/OPTH.S229815
23. Quaranta L., Riva I., Gerardi C. et al. Quality of life in glaucoma: a review of the literature. Adv Ther 2016; 33(6):959-981. https://doi.org/10.1007/s12325-016-0333-6
24. Stalmans I., Sunaric M.G., Cordeiro M.F. et al. Preservative-free treatment in glaucoma: who, when, and why. Eur J Ophthalmol 2013; 23:518-525. https://doi.org/10.5301/ejo.5000270.
25. Antonov A.A., Vostrukhin S.V., Volzhanin A.V. et al. Influence of prostaglandin analogues on intraocular pressure fluctuations in body position change. RMJ Clinical Ophthalmology 2022; 22(2):103-107. https://doi.org/10.32364/2311-7729-2022-22-2-103-107
26. Pupysheva M.M., Gusarevich O.G., Gusarevich A.A., Poloz T.L. Comparing the impact of beta-blockers and prostaglandin analogues on ocular surface change in glaucoma patients. Siberian Scientific Medical Journal 2020; 40(2):61-67. https://doi.org/10.15372/SSMJ20200208
Review
For citations:
Arutyunyan L.L., Anisimova S.Yu., Anisimov S.I., Teuvazhukova D.A. The effect of a preservative-free prostaglandin analogue on the condition of the ocular surface in patients with glaucoma. National Journal glaucoma. 2023;22(4):60-66. (In Russ.) https://doi.org/10.53432/2078-4104-2023-22-4-60-66
Views:
359
Email this article 